- Home
- ICCM vs TELA Comparison
ICCM vs TELA Comparison
Compare ICCM & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | TELA |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 51.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ICCM | TELA |
|---|---|---|
| Price | $0.68 | $1.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $2.50 | ★ $3.31 |
| AVG Volume (30 Days) | ★ 403.0K | 351.8K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,975,000.00 | ★ $77,055,000.00 |
| Revenue This Year | $13.67 | $18.39 |
| Revenue Next Year | $38.55 | $15.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.24 |
| 52 Week Low | $0.59 | $0.86 |
| 52 Week High | $1.66 | $3.12 |
Technical Indicators
Market Signals| Indicator | ICCM | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 41.85 |
| Support Level | $0.67 | $1.09 |
| Resistance Level | $0.73 | $1.28 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 56.00 | 40.89 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About TELA TELA Bio Inc.
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.